SynthesisFrontiers in oncology2026
Association between CYP1A1 gene polymorphisms at rs4646903 and rs1048943 loci and susceptibility to prostate cancer: meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the associations between C allele of CYP1A1 rs4646903 (T>C) and G allele of CYP1A1 rs1048943 (A>G) polymorphisms and prostate cancer (PCa) susceptibility under different genetic models. Methods: We systematically searched PubMed, EMBASE, CNKI, and Wanfang databases from inception to December 31, 2024. Eligible case-control studies were selected. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Meta-analyses were performed using RevMan 5.3 software. Results: Fifteen studies for rs4646903 and 14 studies for rs1048943 were included. For rs4646903 (T>C): The dominant model (CC+CT vs TT) showed that carrying the C allele was associated with increased PCa risk (OR = 1.39, 95%CI: 1.13-1.71, P = 0.002). For rs1048943 (A>G): Carrying the G allele was associated with decreased PCa risk in multiple models: allele model (G vs A: OR = 0.80, 95%CI: 0.71-0.90, P<0.001); homozygous model (GG vs AA: OR = 0.56, 95%CI: 0.42-0.76, P<0.001); dominant model (GA+GG vs AA: OR = 0.72, 95%CI: 0.55-0.94, P = 0.02); recessive model (GG vs GA+AA: OR = 0.78, 95%CI: 0.62-0.99, P = 0.04). Conclusion: The C allele of CYP1A1 rs4646903 may increase PCa risk under the dominant model. The G allele of CYP1A1 rs1048943 may reduce PCa risk across multiple genetic models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.